Phase II, Multicenter, Randomized, Adaptive, Double-blind, Placebo Controlled Study to Assess Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Year Old Spinal Muscular Atrophy (SMA) Patients.

Trial Profile

Phase II, Multicenter, Randomized, Adaptive, Double-blind, Placebo Controlled Study to Assess Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Year Old Spinal Muscular Atrophy (SMA) Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2017

At a glance

  • Drugs Olesoxime (Primary)
  • Indications Spinal muscular atrophy
  • Focus Registrational; Therapeutic Use
  • Sponsors Roche; Trophos
  • Most Recent Events

    • 01 Jul 2017 Primary endpoint (Motor Function Measure) has not been met, according to the results published in the Lancet Neurology.
    • 01 Jul 2017 Results published in the Lancet Neurology
    • 10 Mar 2014 Top-line results reported in a Trophos media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top